Oncology Institute (NASDAQ:STLN) Stock Sold by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Trading Down 6.3%

Shares of NASDAQ:STLN opened at $6.29 on Tuesday. The company’s 50 day moving average price is $6.46. The stock has a market capitalization of $621.70 million, a PE ratio of -20.97 and a beta of 0.39. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.13.

Oncology Institute (NASDAQ:STLN) last posted its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $161.28 million for the quarter, compared to analyst estimates of $152.80 million. On average, equities analysts anticipate that Oncology Institute, Inc. will post -0.21 earnings per share for the current year.

Insider Activity at Oncology Institute

In other Oncology Institute news, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares of the company’s stock, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the purchase, the insider directly owned 10,660,858 shares of the company’s stock, valued at approximately $69,722,011.32. This represents a 0.11% increase in their position. The disclosure for this purchase is available in the SEC filing. 4.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oncology Institute

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new position in shares of Oncology Institute during the 2nd quarter valued at about $961,000. State Street Corp purchased a new position in shares of Oncology Institute during the 2nd quarter valued at about $8,432,000. Bank of America Corp DE purchased a new position in shares of Oncology Institute during the 2nd quarter valued at about $2,129,000. Arrowstreet Capital Limited Partnership lifted its position in Oncology Institute by 169.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock worth $1,288,000 after buying an additional 263,699 shares during the last quarter. Finally, Cetera Investment Advisers lifted its position in Oncology Institute by 427.8% in the 1st quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock worth $394,000 after buying an additional 103,908 shares during the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

STLN has been the subject of a number of recent analyst reports. Needham & Company LLC boosted their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Lake Street Capital began coverage on Oncology Institute in a research report on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective on the stock. BTIG Research lifted their price objective on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings started coverage on Oncology Institute in a research report on Thursday, August 6th. They set a “sell (d-)” rating for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.